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In Japan, the social (medical) health-care system is on the way to being developed to advance personalized medicine through the implementation of cancer genomic medicine, known as "cancer clinical sequencing," which uses a next-generation sequencer. However, no Japanese guidance for cancer genomic testing exists. Gene panel testing can be carried out to help determine patient treatment, confirm diagnosis, and evaluate prognostic predictions of patients with mainly solid cancers for whom no standard treatment is available. This guidance describes how to utilize gene panel testing according to the type of cancer: childhood cancer, rare cancer, carcinoma of unknown primary, and other cancers. The level of evidence classification for unified use in Japan is also detailed. This guidance establishes the basic principles of the quality control of specimens, requirements of medical institutions, informed consent, handling of data during the postanalysis stage, and treatment options based on the evidence level. In Japan, gene panel testing for cancer treatment and diagnosis is recommended to comply with this guidance. This is a collaborative work of the Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, and the Japanese Cancer Association.
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| INTRODUCTION
Progress in the field of molecular biology has facilitated the identification of multiple gene abnormalities (hereinafter referred to as "ge- | 2981 purposes only and refers a guidance that is to be established separately.
Japan has offered its citizens universal health insurance for more than 50 years, and the system for the whole nation covers 70%-90% of the costs for cancer treatment. Novel cancer therapies, such as immune checkpoint inhibitors and targeted therapies matching with genomic molecular alterations, have emerged as promising treatment options in a variety of cancers. Under the national public health insurance scheme, the government controls the prices of all procedures and medications, which impels the use of generic drugs and the development of next-generation sequencing-based diagnostics instead of "one companion diagnostic -one drug"; however, due to the expensive cost of next-generation sequencing, some limitations on usage are required.
Gene panel testing is primarily intended to predict the therapeutic efficacy of novel anticancer drug treatments in eligible patients who have no available options using standard therapy. In principle, testing is limited to once for each patient, but this does not apply to those patients who are able to provide new specimen(s), such as biopsy material, after failure to an anticancer drug. Also, when the gene panel contains genes used for the diagnosis and prognostic prediction, to help determine the appropriate treatment strategy, the frequency of testing is the same as that used for drug efficacy prediction.
Timing of testing is to be decided appropriately according to the type of cancer (see below). Gene panel testing is undertaken, in principle, using a DNA sequencer, sequencing sample preparation reagents, template DNA preparation reagents, and an analysis program that have been approved by the Pharmaceutical and Medical Devices Law.
| APPLICATION OF GEN E PANEL TESTING ACCORDING TO CANCER TYPE
To consider the clinical application of gene panel testing, this guidance first reviews the general use of gene panel testing in solid cancers with regard to the timing of treatment. The subsequent section provides cancer types that should be assessed according to cancer characteristics, particularly when using gene panel testing.
| View on common test population and timing

| Before the start of drug therapy
Testing is carried out primarily in patients with solid cancers who are eligible for drug therapy with no standard therapy available. In principle, the primary purpose for undertaking gene panel testing prior to treatment is to obtain relevant genomic mutation data that would aid in selecting an appropriate treatment strategy. The gene panel could also contain genes useful for diagnosis and prognostic prediction. For instance, a treatment associated with a better prognosis to a known genomic mutation will be assigned to a patient with a matching profile. Also at this point, when a portion of genes loaded on the gene panel has already been approved and is used as a companion diagnostic, the guidelines issued by the relevant medical governing body should be followed to determine standard therapy. 
|
| Carcinoma of unknown primary
Carcinoma of unknown primary often requires time for diagnosis and determination of therapeutic strategy. Therefore, gene panel testing is undertaken to support diagnosis based on the findings of genomic mutations and to select a therapeutic drug that is likely to be effective.
| Other cancers
For handling of hematopoietic malignancies and hereditary tumors, refer to guidelines and guidance stipulated separately by the relevant medical governing bodies.
| QUALITY CON TR OL OF SPECIMEN S USED FOR GENE PANEL TESTING
Gene panel testing uses specimens that are under appropriate quality control, with reference to The Japanese Society of Pathology Guidelines on the Handling of Pathological Tissue Samples for Genomic Medicine 1 or other relevant regulations. 
| REQUIREMENTS FOR MEDICAL INSTITUTIONS/ LABORATORIES CARRYING OUT GEN E PANEL TESTING
| Evidence level-based classification
The definition of evidence level for individual genomic mutations acquired by gene panel testing should not differ greatly from the definitions standardized in the USA and EU. 4 The definitions adopted in this guidance (Table S1 ) have been developed to be suitable for the medical system in Japan, while paying attention to maintaining consistency with those published in the USA and EU. Table   S1 also provides actionable examples for evidence levels that are relevant to specific levels of therapeutic efficacy. Actionable examples based on the evidence level of genes that are related to "diagnosis"
or "prognosis" may be further amended at a later date to reflect new or accumulated findings. Information acquired by gene panel testing is described in a standardized manner based on the evidence level defined in this guidance, whenever possible, using the evidence levels listed in Table S2 as well as cancer genome knowledge databases (Table S3 ). This guidance covers experimental gene panels comprised of cancer-related genes that are under development or in preparation for development in Japan, when requested by the deadline, and are assigned individual evidence levels based on the evidence classification adopted in this guidance. Following external review, the genes and their evidence levels are summarized in 
| Description of therapeutic options
Efforts should be made to provide therapeutic options based on genomic mutation-specific cancer type indications and evidence levels to date as well as other information, such as cancer genome knowledge databases operated in and outside Japan. In principle, when the evidence level is 2 or greater, the patient should be trea- 
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